Jim Cramer -- Gilead Needs to Make an Acquisition - TheStreet

Shares of Gilead Sciences (GILD) - Get Report were downgraded to market perform by Leerink Partners, with a price target of $93. 

The analysts say the Hepatitis C market is eroding. However, TheStreet's Jim Cramer said investors shouldn't give up on the Hep. C market. Instead they should simply realize that Gilead needs to make an acquisition. 

Historically, Gilead has been more of a conservative company when it comes to M&A. However, because of a recent bond offering, the company has a ton of flexibility and can afford to make a huge acquisition if it wants to, Cramer, the co-manager of the Action Alerts PLUS portfolio, explained on CNBC's "Stop Trading" segment. 

So what should Gilead acquire? How about GW Pharmaceuticals (GWPH) - Get Report or Alkermes (ALKS) - Get Report , two sub-$7.5 billion companies that are working on anti-opioid drugs. 

Opioids are the country's secret epidemic, he said. They lead to far too many deaths, which is something not nearly enough people are talking about. Something needs to be done about it and these two companies could help on that front, Cramer concluded. 

Image placeholder title

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.